ホーム>>Signaling Pathways>> MAPK Signaling>> NKCC>>Bumetanide

Bumetanide (Synonyms: PF-1593, Ro 10-6338)

カタログ番号GC15524

非常に強力なループ利尿薬であるブメタニド (Ro 10-6338; PF 1593) は、Na+-K+-Cl+ 共輸送体 (NKCC) ブロッカーです。

Products are for research use only. Not for human use. We do not sell to patients.

Bumetanide 化学構造

Cas No.: 28395-03-1

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$70.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bumetanide (Ro 10-6338;PF 1593) is a selective Na+-K+-Cl- cotransporter 1 (NKCC1) inhibitor, weakly inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[4].

References:
[1]. Frelin C, et al. Biochemical characterization of the Na+/K+/Cl- co-transport in chick cardiac cells. Biochem Biophys Res Commun. 1986 Jan 14;134(1):326-31.
[2]. Lykke K, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy Behav. 2016 Jun;59:42-9.
[3]. Bourrit A, et al. Basic characterization of an ouabain-resistant, bumetanide-sensitive K+ carrier-mediated transport system in J774.2 mouse macrophage-like cell line and in variants deficient in adenylate cyclase and cAMP-dependent protein kinase activities. Biochim Biophys Acta. 1985 Jul 11;817(1):85-94.
[4]. Sandstr m PE. Evidence for diabetogenic action of bumetanide in mice. Eur J Pharmacol. 1988 May 20;150(1-2):35-41.

レビュー

Review for Bumetanide

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bumetanide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.